Add sublingual immunotherapy to your practice
Adding sublingual immunotherapy is a clinical service decision, not simply opening a pharmacy account. Before the first prescription, your practice needs a defined patient population, a competent prescribing clinician, a product-specific safety plan, a dispensing handoff, and a reliable way to follow patients after they leave the office. This guide turns those decisions into an accountable launch workflow.
U.S. practice planning for environmental allergic rhinitis, with or without allergic asthma. This is not a prescribing protocol, a dosing guide, a food-allergy program, a pharmacy-selection comparison, or authorization to practice beyond your training or license. The 2024 inhalant-immunotherapy guideline applies to patients aged 5 years and older; its scope is not a blanket eligibility rule for children or for any particular product. Clinical and legal review of this manuscript remain pending.
1. Define the clinical service before choosing an ordering system
Start with a written environmental-allergy service scope. The 2024 Clinical Practice Guideline: Immunotherapy for Inhalant Allergy recommends offering immunotherapy, or referral to a clinician who can offer it, for allergic rhinitis with or without allergic asthma when symptoms are inadequately controlled with medical therapy, allergen avoidance, or both, or when the patient prefers immunomodulation. It assumes underlying conditions and other contributing factors have already been addressed. A positive test or a recurring symptom alone is not the service-entry criterion.
Specify whether the practice will evaluate candidates, prescribe FDA-approved SLIT tablets, prescribe patient-specific compounded liquid SLIT, provide office-based SCIT, or refer for one or more of these services. Separate the clinical decision from a vendor enrollment decision. Do not automatically convert an existing injection or tablet prescription into liquid SLIT: the prescriber must reassess the indication, formulation, evidence, and supervision plan.
Keep food allergy, drug allergy, venom allergy, and complex conditions outside this environmental launch pathway. A company page may describe broader programs; that does not extend the scope of an inhalant guideline or establish that a general practice is ready to deliver them. Food or drug allergy requires individualized specialist evaluation in person before a separate treatment pathway is considered.
- Record the conditions you will manage, the routes you will offer, the limits of clinician competence, and the cases you will refer.
- Name the clinician responsible for patient selection and the clinician covering that responsibility during absences.
- Identify an in-person allergy referral pathway before enrollment begins, including how referrals and recommendations return to your medical record.
2. Make route selection a shared clinical decision
The inhalant guideline calls for explaining SCIT, SLIT tablets, and aqueous SLIT in terms of risks, benefits, convenience, and cost. Discuss continued symptom management and exposure reduction as well. Each choice has strengths and limits; the aim is a treatment that fits the patient and the practice, not a predetermined winner.
Do not transfer a tablet trial, an injection protocol, or a study of another liquid formulation to the exact compounded prescription you intend to use. The AAAAI/ACAAI 2017 SLIT practice parameter emphasizes formulation-specific evidence and does not endorse off-label aqueous SLIT. The 2024 guideline discusses aqueous SLIT as an option with off-label status and evidence limitations. These are not interchangeable endorsements of a vendor protocol.
On smaller screens, scroll the table horizontally to read every column.
| Approach | Potential fit | Limit to explain |
|---|---|---|
| FDA-approved SLIT tablet | A patient whose clinically relevant allergen and indication match an approved product, and who can follow its home-treatment and emergency plan. | Product-specific indications, contraindications, and eligibility apply. Tablets do not provide a custom mixture for every sensitization. Follow the current label for the exact medication. |
| Patient-specific compounded liquid SLIT | A clinician may consider a customized sublingual prescription after assessing the patient and the evidence relevant to the proposed formulation. | The final drops are not FDA-approved. Liquid and multiallergen evidence cannot be assumed equivalent to approved tablets. Prescriber accountability and a defined safety protocol remain necessary. |
| Office-based SCIT or referral for SCIT | A patient who prefers supervised treatment visits or whose selected allergens and clinical circumstances fit an injection program. | Requires an appropriately equipped clinical setting, repeated visits, and reaction monitoring. Coverage depends on benefits; this guide supplies no home-injection instructions. |
| Symptom treatment and exposure reduction | Patients whose symptoms can be managed without starting immunotherapy, or who are not currently suitable for it. | May require ongoing management and reassessment. Choosing not to start immunotherapy is a legitimate clinical decision, not a failed enrollment. |
3. Establish clinician competency, not just vendor access
The clinician performing allergy skin testing or administering immunotherapy must be able to diagnose and manage anaphylaxis, according to the inhalant guideline. Operating within professional scope and training applies regardless of which pharmacy prepares the prescription. A vendor account, a protocol manual, or a training attendance record is not a substitute for demonstrated clinical competence.
Create a competency plan covering allergic versus nonallergic disease, history-guided test selection and interpretation, asthma assessment, route and allergen selection, consent, adverse-reaction assessment, and emergency response. For staff, distinguish tasks they can perform under an approved workflow from decisions that require the prescriber. Use supervised instruction and observed performance appropriate to each role; record who signs off competence and how coverage staff are trained.
Allergychoices describes La Crosse Method training, tailored skin-testing implementation, pharmacist consultation, and physician advisors. Its skin-testing page describes developing panels for regional and patient needs, coordinating supplies, training the team, and applying results to treatment. These are company-described educational and operational services, not an independent certification that a clinician is qualified or that a particular prescription is effective.
- Ask for the current curriculum, instructor qualifications, prerequisites, supervised learning opportunities, and the process for handling questions beyond the training scope.
- Request the current protocol and clarify which parts concern environmental liquid SLIT, which concern other programs, and which differ from guideline recommendations or approved-product labeling.
- Assess your own staffing time, appointment capacity, emergency equipment, and referral access. Do not treat company statements about no added overhead as proof that your clinical service has no implementation costs.
4. Build a diagnostic workup that connects tests to symptoms
The guideline distinguishes sensitization from clinical allergy: skin-test positivity or allergen-specific IgE can occur without symptoms on exposure. The clinician should select only clinically relevant allergens that correlate with the history and are confirmed by testing. A polysensitized patient does not necessarily need treatment for every positive result.
Collect the symptom pattern, seasonality, relevant home and work exposures, effect on sleep and daily activity, prior treatments and response, asthma history, and a clinical examination. Use skin testing or serum allergen-specific IgE as clinically appropriate, then document how the results fit the exposure history. Conflicting symptoms and test results require reassessment rather than automatic formulation of a prescription.
Evaluate for asthma before immunotherapy, or refer to someone who can. Assess control and obtain objective lung-function assessment when clinically indicated. Reconcile medications and comorbidities that could affect reaction risk or emergency treatment. Testing staff must work within a clinician-approved process with anaphylaxis capability; asking a vendor for testing supplies does not complete the diagnostic workup.
Allergychoices accepts existing testing within its described enrollment workflow and offers diagnostic support. That operational flexibility does not relieve the prescriber of deciding whether the results are sufficient and relevant for the current patient. Do not promise serial testing as proof of benefit: the inhalant guideline discourages repeat allergy testing solely to assess ongoing efficacy unless exposures change or symptom control is lost.
5. Use a selection gate and an in-person referral gate
Before accepting a patient, document the indication, clinically relevant allergens, asthma assessment, medication review, route choice, ability to follow treatment, and access to emergency care. The inhalant guideline says not to initiate immunotherapy during pregnancy, with uncontrolled asthma, or when a patient cannot tolerate injectable epinephrine. Asthma must be assessed again when subsequent treatment is being considered; home administration does not remove that responsibility.
For this environmental-service launch, use a conservative in-person specialist assessment gate for a history of anaphylaxis, uncontrolled asthma, food or drug allergy, young children, and pregnancy. This is a proposed practice-readiness guardrail, not a claim that every guideline requires the same visit format. Do not enroll these cases through a generic online screening or an automatic test-to-prescription process. Specialist review does not override a contraindication in the selected medication label.
The guideline identifies beta-blocker use, anaphylaxis history, systemic immunosuppression, and eosinophilic esophagitis for SLIT as reasons a clinician may choose not to initiate treatment. Product labels can be more restrictive: ODACTRA, for example, contraindicates a history of any severe systemic allergic reaction, severe local reactions to sublingual immunotherapy, and eosinophilic esophagitis. Apply the actual product label rather than a generalized eligibility statement.
A child needs developmentally appropriate assessment, caregiver education, and a formulation-specific decision; guideline age scope is not product approval and is not evidence for treating younger children. Pregnancy in a patient already receiving maintenance therapy calls for individualized reassessment, not an assumption that initiation and continuation are the same decision. Uncontrolled asthma requires evaluation and control before immunotherapy is reconsidered.
- Pause the pathway when the diagnosis is uncertain, the reaction history is complex, or the patient cannot demonstrate the safety plan.
- Document the referral question, relevant history and test records, the requested in-person assessment, and who will act on the specialist recommendation.
- Keep referral status visible in the record; a pharmacy order should not bypass an unresolved clinical decision.
6. Assign ownership at every handoff
The following responsibility map is a proposed practice workflow. Confirm it with your clinicians, staff, dispensing pharmacy, and any program vendor before launch. Consultation and dispensing support help a practice operate; they do not transfer patient-selection or prescribing authority to an ordering portal.
On smaller screens, scroll the table horizontally to read every column.
| Role | Owns or performs | Handoff that must be explicit |
|---|---|---|
| Prescribing clinician | Diagnosis; candidacy and referral; route and allergen selection; prescription authorization; consent; supervision and emergency plan; reaction assessment; treatment changes, interruptions, and discontinuation. | Give staff and pharmacy the authorized plan and a reachable clinical contact. Record consultation advice and the prescriber’s resulting decision. |
| Clinical staff | History collection and testing within scope; reconciliation; education and teach-back; scheduling; message triage; tracking outstanding orders and follow-up under clinician-approved procedures. | Escalate clinical concerns instead of changing treatment independently. Identify who reads the inbox and who covers it when the usual team is absent. |
| Dispensing pharmacist | Prescription review and clarification; preparation and dispensing within applicable requirements; patient-specific labeling and counseling; product quality, storage information, and traceability. | Resolve ambiguities with the prescriber. Communicate dispensing, product concerns, patient questions, and needed prescription changes through an agreed channel. |
| Program vendor or educational support | Training resources, implementation assistance, portal support, and consultations within the services actually agreed in writing. | Specify what is advice versus an authorized order, availability of support, and how unresolved clinical questions reach the treating clinician. |
| Practice billing and scheduling team | Itemized estimates; benefit checks; clear payment communications; follow-up scheduling and identification of cost-related interruptions. | Do not promise coverage or a clinical outcome. Notify the clinical team when financial barriers threaten continuity. |
7. Obtain product-specific informed consent
Consent should name the actual route and formulation, the reason for treatment, the allergens selected, alternatives, relevant evidence limitations, possible local and systemic reactions, and the patient’s responsibilities. Explain that treatment is not immediate symptom relief or a guaranteed cure. Keep an appropriate symptom-management plan rather than presenting immunotherapy as a substitute for all other care.
For compounded liquid SLIT, say that the prescription is patient-specific and uses allergenic extracts off-label by the sublingual route, and that the final compounded drops are not FDA-approved. Allergychoices states that its pharmacy uses FDA-approved allergenic extracts; approval of the source extract does not approve the final mixture, oral route, or treatment claim. Off-label status is not by itself a conclusion that a treatment is unsafe, but it is not a universal assurance of safety or efficacy either.
Include the emergency plan, when the patient should contact the practice, clinician-directed interruption and restart decisions, follow-up expectations, and the full payment discussion. Ask the patient or caregiver to explain these points in their own words. Document the conversation and unresolved questions, not only a signature.
Clinical consent is not a regulatory exemption. FDA’s January 2018 biologics guidance states in Section II.C that biologics do not qualify for the compounded-drug exemptions under sections 503A and 503B. Section III.C concerns allergenic prescription sets for subcutaneous immunotherapy, not oral SLIT. Have the practice and pharmacy confirm the applicable regulatory basis and state requirements; do not use that SCIT policy as a general approval of compounded oral drops.
- Clinical Practice Guideline: Immunotherapy for Inhalant Allergy (2024)
- AAAAI/ACAAI: Sublingual immunotherapy — focused practice parameter update (2017)
- Allergychoices: Allergychoices Pharmacy
- FDA: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved BLA (January 2018)
- FDA: ODACTRA prescribing information, revised June 2026
8. Close the loop from authorized prescription to patient receipt
Allergychoices’ become-a-provider page describes an identify, test, and treat workflow, followed by prescriptions submitted by fax, phone, or its secure pharmacy portal. Its pharmacy page describes named-patient preparation according to provider prescriptions, lot tracking, counseling, and portal ordering and tracking. Confirm the current accepted channels and the exact information the pharmacy needs during implementation; public descriptions are not a substitute for a complete current order specification.
Build a closed-loop process in your medical record. The workflow below intentionally does not provide a dose, concentration, mixing recipe, escalation schedule, or universal storage window. Those belong in the clinician-authorized prescription and the dispensing pharmacy’s patient-specific instructions.
- Clinical authorization: record the diagnosis, relevant history and test findings, selected allergens and route, consent, supervision plan, and follow-up plan before transmitting the order.
- Order completeness: confirm patient identifiers, prescriber credentials and contact, relevant allergy and medication information, the complete authorized prescription, and delivery and counseling arrangements. Obtain patient permission for appropriate information sharing.
- Pharmacy clarification: use a named staff owner to track receipt and questions. Route formulation, regimen, or other clinical ambiguities to the prescriber; do not let staff infer missing instructions from a prior order.
- Dispensing confirmation: establish how the practice learns that an order was accepted, clarified, dispensed, delayed, or cancelled. Clarify who contacts the patient about payment, shipment, and unresolved questions.
- Patient receipt: have the patient check identity and label, review the actual instructions, and report discrepancies, damage, or a storage concern to the pharmacy before using a questionable product. Retain enough prescription and product information for a recall or reaction investigation.
- Treatment clearance: confirm that required supervision and education are complete before use. Receipt of a bottle is not permission to start when the clinician has required an in-person initiation visit.
- Refills: set a clinician-approved review process for symptoms, reactions, interruptions, medication changes, and current instructions. A refill request is not an automatic authorization to change or restart therapy.
9. Write a medication-specific supervision and emergency plan
For an FDA-approved tablet, use the current prescribing information for that exact medication. ODACTRA’s FDA label, revised June 2026, requires the first dose in a healthcare setting under an experienced healthcare professional, preparation to manage a life-threatening reaction, and observation for at least 30 minutes. It also requires prescribing epinephrine and training the patient or caregiver, with immediate medical care after epinephrine use. This is a specific tablet-label requirement, not an FDA-approved liquid-SLIT protocol.
For compounded liquid SLIT, the prescriber must document the initiation setting, observation and reassessment approach, patient-specific epinephrine plan, home-use clearance, and escalation pathways using the selected formulation and clinical circumstances. The inhalant guideline describes initial SLIT administration under medical supervision with asthma assessment and emergency education. Lack of an approved liquid label is not permission to omit supervision; do not assume that the tablet label establishes the safety or precise protocol for a compounded liquid.
The practice needs a clinician-approved office response process, staff trained to recognize and manage anaphylaxis within their roles, immediately accessible emergency supplies, and a plan to activate emergency medical services. Rehearse the response and the transfer of patient information. The guideline identifies epinephrine as first-line treatment for systemic allergic reactions; antihistamines should not replace it.
Give patients a written action plan distinguishing routine communication from an emergency. Breathing difficulty, significant throat or tongue swelling, collapse or faintness, or a suspected systemic allergic reaction should trigger the individualized emergency plan and urgent medical care, not waiting for a portal reply. Train the patient or caregiver on the prescribed emergency medication and document demonstration of its use without replacing its own prescribing instructions.
10. Use teach-back and give patients one clear communication plan
Use the actual prescription label and written clinician instructions during teaching. Ask the patient or caregiver to demonstrate the relevant device and explain the route, routine, storage and beyond-use information, and what to do if instructions conflict. Do not copy storage or beyond-use periods from another formulation or infer them from a supply duration.
Provide a named practice contact for symptoms and treatment decisions, a pharmacy contact for dispensing and product questions, the method for after-hours clinical concerns, and emergency instructions. Explain which messages are not monitored urgently. Allergychoices describes counseling, multilingual interpreter services, and adherence tools; confirm what is available for the patient and what the practice must provide itself.
- Ask: “What is this treatment intended to help, and what would you use for immediate symptom relief?”
- Ask: “Which symptoms mean you follow the emergency plan rather than message the office?”
- Ask: “Who do you call about a reaction, a missed treatment period, a new medicine, or an upcoming procedure?”
- Ask: “How will you check that the prescription is yours, follow its storage instructions, and recognize when it should no longer be used?”
- Ask: “What will you do if a refill, shipment, or payment problem interrupts treatment?” Record barriers, arrange support, and return unresolved clinical questions to the prescriber.
11. Follow patients through adherence problems, reactions, and interruptions
Schedule follow-up before treatment begins and explain how the patient obtains an earlier review. Use a clinician-set schedule appropriate to the route, phase, risk, and symptoms rather than claiming one universal interval. At review, assess symptom burden, use of symptom medications, function, asthma control, adherence, adverse effects, and changes in exposure or other medicines. The inhalant guideline favors clinical outcomes over serial allergy tests as a routine measure of benefit.
Track refill delays, missed visits, difficulty following instructions, and affordability barriers so they reach the clinical team. A shipment or adherence tool cannot establish that the patient actually used treatment correctly or is ready for the next prescription. Ask what happened and what support the patient needs.
The prescriber must assess reactions and decide whether treatment continues, changes, pauses, or ends. Do not label every oral symptom harmless or tell patients to push through worsening symptoms. For ODACTRA specifically, the label discusses serious allergic reactions, persistent or escalating mouth or throat reactions, severe or persistent gastroesophageal symptoms, asthma exacerbations, and oral wounds or inflammation. These product-specific precautions are not an identical checklist or restart rule for every compounded prescription.
Give written instructions for contacting the prescriber about treatment gaps, reactions, new illness or medicines, pregnancy, and oral surgery or lesions. Restart decisions must use the actual medication instructions and clinical assessment; do not provide a generic gap length, dose-reduction formula, catch-up schedule, or self-restart permission. The ODACTRA label notes limited restart-safety data, which is a reason to avoid casual extrapolation.
Discuss duration as a longitudinal decision. The inhalant guideline recommends a minimum of three years for patients experiencing symptomatic control, with ongoing duration based on response. That recommendation is not a guaranteed outcome for a particular compounded mixture. Reassess benefit, burden, safety, and preference; document why treatment continues or ends and how other allergy care will continue.
12. Explain the complete bill before the first order
Separate the practice’s implementation costs from the patient’s treatment costs. Allergychoices provides pharmacy prescription pricing by phone and describes direct patient billing; its skin-testing service offers a customized training quote. These are not a published all-in budget for your practice or a total patient-care price. A complete practice-specific implementation price is not published in the cited pages; request a written scope and quote.
Give the patient an itemized estimate with the payee, service, expected timing, recurring versus one-time charges, and what is excluded. Obtain benefits information for the exact service and product, distinguish medical from pharmacy benefits, and explain deductible, copay, coinsurance, network, referral, and authorization requirements when applicable. Benefit verification is not a payment guarantee.
Medicare NCD 110.9 states noncoverage for antigens prepared for sublingual administration, describing drops placed under the tongue. This is a Medicare national coverage policy for those antigens, not a universal statement about all insurers, all allergy services, or FDA-approved tablet pharmacy benefits. Verify testing and consultation benefits separately and check the patient’s applicable plan; do not reclassify a sublingual prescription as an injection service to obtain payment.
Before ordering, clarify who collects payment, when an order is released, recurring refill authorization, shipping and replacement costs, cancellation and refund terms, and what happens if treatment is paused. Do not promise reimbursement, a refund, or financial assistance unless the applicable written terms support it. If cost threatens continuity, discuss alternatives with the clinician rather than leaving the patient to ration or restart treatment alone.
On smaller screens, scroll the table horizontally to read every column.
| Cost item | What the practice should clarify |
|---|---|
| Initial assessment and testing | Practice and laboratory charges; whether tests are clinically indicated; applicable benefits and out-of-pocket responsibility. |
| Prescription product | The actual prescribed formulation and supply; the dispensing pharmacy’s written quote; what changes could alter the charge. |
| Initiation and follow-up care | Required supervised visits, scheduled reviews, additional clinical assessments, and how those services are billed. |
| Emergency medication and symptom care | Separate medication or device costs and benefits, including renewal or replacement needs. |
| Delivery and service terms | Shipping, replacement, refill payment authorization, cancellations, and refunds, using the current written terms rather than assumptions. |
13. Use the Allergychoices inquiry workflow to resolve operational questions
Allergychoices’ become-a-provider page links directly to its provider request-a-call form for building an allergy program. Use that live provider inquiry page to discuss your intended environmental scope and current needs. For testing implementation, its skin-testing page links to the Diagnostics Inquiry page for a tailored training package and quote.
Bring a concrete workflow to the conversation: who prescribes, who needs training, whether diagnostics are already available, which patients are outside your scope, how orders enter the medical record, and how reactions and interruptions return to the clinician. Ask for the current provider onboarding requirements, educational materials, prescription instructions, secure portal setup, pharmacy clarification process, and patient counseling resources.
Ask how pharmacist and physician-advisor consultations are requested, their availability, and what happens when a question exceeds the program’s support scope. Confirm how recalls, shipping problems, label concerns, and reports of reactions are communicated. Allergychoices describes these support services publicly; their precise implementation in your practice must be agreed, not assumed.
Treat company statements about broad candidacy, safety, validated outcomes, or easy implementation as company claims. They do not replace clinical guidelines, formulation-specific evidence appraisal, actual professional credentials, regulatory review, or your own readiness assessment. This page uses company sources to describe the offered workflow, not to certify its efficacy or rank it against other programs.
- Allergychoices: Get Started to Becoming a Provider
- Allergychoices: Provider Inquiry — Request a Call or Email
- Allergychoices: Allergy Skin Testing Training
- Allergychoices: Diagnostics Inquiry
- Allergychoices: Clinical Practice Support
- Allergychoices: Allergychoices Pharmacy
- Allergychoices: About the La Crosse Method Practice Protocol
14. Use a launch-readiness checklist with a real stop rule
This is a proposed operational checklist derived from the clinical and service requirements above, not an accreditation standard. Assign an owner and record completion evidence for each item. If a safety-critical item is unresolved, defer enrollment or refer the patient instead of treating an open pharmacy account as launch clearance.
- Clinical scope approved: environmental indications, routes offered, exclusions, in-person assessment gates, and referral pathways are documented.
- People ready: a prescriber and backup are named; clinical competence and role-appropriate staff training are documented; specialist consultation and referral access are usable.
- Diagnostics ready: history, examination, relevant testing, sensitization-to-symptom interpretation, medication reconciliation, and asthma assessment are part of the record.
- Product decision ready: the clinician has reviewed the exact formulation’s evidence, approved-product label when applicable, contraindications, and regulatory considerations with appropriate pharmacy or legal input.
- Consent ready: route-specific risks, off-label compounded-liquid status when relevant, alternatives, expectations, emergency planning, and costs are accurately described without outcome guarantees.
- Supervision ready: the actual initiation setting and observation plan are defined; office staff, supplies, and emergency response are prepared; the patient’s emergency-medication and home-clearance plan is recorded.
- Order loop ready: the practice has named owners for transmission, clarification, dispensing confirmation, receipt problems, recalls, and clinically authorized refills.
- Communication ready: patients know the clinical, pharmacy, after-hours, and emergency channels; teach-back and caregiver needs are documented.
- Continuity ready: follow-up is scheduled; adherence barriers and reactions are tracked; interruptions cannot silently turn into an unsupervised restart.
- Payment ready: implementation obligations and patient charges are separated; itemized estimates and applicable benefit limits are clear; current payment and cancellation terms are available.
- Practice rehearsal complete: walk a sample case through diagnosis, referral, consent, order clarification, a reported reaction, a refill delay, and clinician-directed reassessment without issuing a patient prescription.
- Clinical Practice Guideline: Immunotherapy for Inhalant Allergy (2024)
- AAAAI/ACAAI: Sublingual immunotherapy — focused practice parameter update (2017)
- FDA: ODACTRA prescribing information, revised June 2026
- FDA: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved BLA (January 2018)
- Allergychoices: Get Started to Becoming a Provider
- Allergychoices: Clinical Practice Support
- Allergychoices: Allergychoices Pharmacy
- CMS National Coverage Determination 110.9: Antigens Prepared for Sublingual Administration
Frequently asked questions
Can a practice start prescribing as soon as it has a pharmacy account?
No. An account provides ordering access, not clinical competence or patient clearance. Before enrollment, establish professional scope, relevant diagnostic capability, a responsible prescriber, referral access, product-specific consent and supervision, emergency readiness, and follow-up. The inhalant guideline requires clinicians performing skin testing or administering immunotherapy to be able to diagnose and manage anaphylaxis.
Does a positive allergy test mean that allergen should be in the prescription?
Not automatically. Sensitization can exist without clinical allergy. Select allergens that are relevant to the patient’s symptoms and exposure history and confirmed by testing. A panel result does not replace the clinician’s interpretation; treatment need not include every positive test.
Are compounded drops equivalent to FDA-approved SLIT tablets?
They are different formulations with different regulatory status and evidence. FDA-approved tablets have product-specific indications and labeling. The final compounded drops are not FDA-approved, even when made from FDA-approved allergenic extracts. The AAAAI/ACAAI practice parameter cautions against assuming equivalence and does not endorse off-label aqueous SLIT; the 2024 inhalant guideline discusses aqueous SLIT with its limitations. Appraise the actual proposed prescription rather than borrowing a tablet’s evidence.
Does every SLIT prescription have the same first-dose and epinephrine protocol?
No. Follow the current label for the exact FDA-approved tablet: ODACTRA, for example, requires supervised initiation, at least 30 minutes of observation, prescribed epinephrine, and training. Compounded liquid SLIT has no FDA-approved liquid label to apply; the prescriber must establish and document a formulation- and patient-specific supervision and emergency plan. The inhalant guideline’s supervised-initiation discussion does not turn liquid SLIT into an approved product or remove the need for individualized assessment.
Which patients need a specialist or an in-person assessment before this pathway?
This launch guide uses an in-person specialist assessment gate for anaphylaxis history, uncontrolled asthma, food or drug allergy, young children, and pregnancy, rather than automatic enrollment. That is a conservative implementation guardrail, not a universal guideline visit-format mandate. Do not initiate immunotherapy during pregnancy or with uncontrolled asthma, and apply the actual product’s contraindications. A specialist visit does not make a contraindicated medication suitable.
Does adding an environmental allergy service qualify the practice to offer food SLIT?
No. This workflow and the inhalant guideline concern environmental allergic rhinitis, with or without allergic asthma. Company descriptions of food programs do not establish eligibility, competence, or evidence for a separate food treatment service. Patients with food or drug allergy need individualized specialist assessment in person and a separate diagnostic and treatment pathway.
Who decides what happens after a reaction or treatment interruption?
The treating prescriber decides whether to reassess, continue, modify, pause, restart, or discontinue treatment, using the actual medication instructions and the clinical circumstances. Staff can collect information and triage under an approved plan; pharmacists can counsel and clarify prescriptions. Patients should follow their emergency plan for serious symptoms and contact the clinician about interruptions rather than invent a catch-up or restart schedule.
Should repeated allergy tests be used to prove that treatment is working?
Not routinely. The inhalant guideline recommends avoiding repeat testing solely to assess ongoing immunotherapy efficacy unless environmental exposures change or symptom control is lost. Follow symptom burden, symptom-medication use, function, asthma control, adherence, and safety. A smaller test response is not a substitute for clinical benefit.
Does Medicare noncoverage mean no insurer covers any part of allergy care?
No. Medicare NCD 110.9 addresses antigens prepared for sublingual administration and describes drops placed under the tongue. Do not extend it to every payer, allergy assessment, test, consultation, or FDA-approved tablet pharmacy benefit. Verify the exact patient plan, service, product, benefit category, and out-of-pocket responsibility, and separate a pharmacy product quote from the practice’s medical charges.
How does a practice request Allergychoices implementation help?
Use the provider request-a-call page linked from Allergychoices’ become-a-provider workflow. Bring your environmental scope, staffing and training needs, existing diagnostics, referral plan, ordering and follow-up processes, and cost questions. Use the linked Diagnostics Inquiry workflow for tailored skin-testing implementation. Confirm current onboarding, education, pharmacy communication, and support terms in writing rather than assuming the public page is a complete service agreement.
Regulatory scope
Personalized allergy drops are compounded and prescribed off-label using FDA-approved allergenic extracts; the final compounded drops are not FDA-approved. Approval of an extract does not approve a final mixture or its sublingual use. Off-label status alone is neither a finding that treatment is unsafe nor a guarantee of safety or effectiveness. FDA’s January 2018 biologics guidance states that biologics do not qualify for the compounded-drug exemptions under sections 503A and 503B; its Section III.C policy for allergenic prescription sets concerns subcutaneous immunotherapy, not oral SLIT. This guide does not establish a regulatory exemption or certify a pharmacy’s compliance.
Discuss practice onboarding
Ask Allergychoices about its published education, support and prescription workflow.
Sources
- Clinical Practice Guideline: Immunotherapy for Inhalant Allergy (2024)
Original guideline, published March 2024 and deposited in PMC in 2025. Applies to inhalant allergy in patients aged 5 years and older, not all pediatric ages or food/drug programs. Table 1 distinguishes sensitization and clinical allergy. KAS 1–4, 7–8, and 10–12 support candidacy, contraindications and individualized risk, asthma assessment, route education, clinically relevant allergens, anaphylaxis capability, clinical follow-up rather than routine retesting, and response-based duration. The checklist and in-person launch gates here are operational adaptations, not quoted mandates or certification.
- AAAAI/ACAAI: Sublingual immunotherapy — focused practice parameter update (2017)
Original professional-society practice parameter. Primarily concerns FDA-approved tablets; statements 4–6, 8, and 9 address formulation non-equivalence, supervised initiation, emergency education, follow-up, and lack of endorsement for off-label aqueous SLIT. Its historical tablet list, age ranges, dosing and interruption examples are not used as current labels or liquid protocols.
- FDA: ODACTRA prescribing information, revised June 2026
Current label read October 12, 2026. Specific to the house-dust-mite sublingual tablet: indication, contraindications, supervised first dose, at least 30-minute observation, prescribed epinephrine and training, serious and local reactions, eosinophilic esophagitis, asthma, oral conditions, and limited restart data. Not approval or a dosing/safety protocol for compounded liquid SLIT; numeric product ages and doses are deliberately not reproduced.
- FDA: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved BLA (January 2018)
Agency guidance, not an oral-SLIT approval. Section II.C states that biologics are not eligible for the 503A/503B compounded-drug exemptions. Section III.C addresses allergenic prescription sets for SCIT specifically. Neither section establishes a general exemption or approved-product status for compounded oral SLIT.
- CMS National Coverage Determination 110.9: Antigens Prepared for Sublingual Administration
Original Medicare national policy with effective date November 17, 1996; coverage text verified in the official page HTML because the reader view omits the decision body. Describes noncoverage of antigens administered as drops under the tongue. Used only for that Medicare coverage scope, not as a current comparative efficacy conclusion, an all-payer rule, or a tablet pharmacy-benefit determination.
- Allergychoices: Get Started to Becoming a Provider
Company-described identify/test/treat enrollment workflow, existing-test use, fax/phone/secure-portal prescription channels, direct patient billing, and link to provider inquiry. Company claims about no overhead, broad candidacy, safety, and outcomes are not treated as independent clinical evidence or a practice-specific budget.
- Allergychoices: Provider Inquiry — Request a Call or Email
Live official provider inquiry destination for discussing an allergy program. Confirms a contact workflow, not guaranteed acceptance, clinician competence, or service terms.
- Allergychoices: About the La Crosse Method Practice Protocol
Company description of a customizable protocol and environmental, food, and preseasonal program links. Used to identify educational/service scope only. Broad safety, age, efficacy, scale, and validation claims are not transferred to this environmental implementation guide as independent evidence or regulatory approval.
- Allergychoices: Allergist Training to Expand Your Treatment Options
Company offer of La Crosse Method training and link to request information. Does not establish accreditation, board certification, an independent competency assessment, or an endorsement of treatment for all ages or complex conditions.
- Allergychoices: Allergy Testing Diagnostics
Company diagnostic implementation services, devices, supplies, associated training, and linked testing-support pages. Clinical interpretation and candidacy in this guide rely on the inhalant guideline rather than company marketing.
- Allergychoices: Allergy Skin Testing Training
Official description of region/patient-specific panels, supply coordination, team training, application of testing to the protocol, and tailored training packages with a customized quote via Diagnostics Inquiry. Does not publish a complete practice implementation price or certify clinical readiness.
- Allergychoices: Diagnostics Inquiry
Live official diagnostics contact destination linked from skin-testing implementation. Not evidence of a specific training package, price, or approval.
- Allergychoices: Clinical Practice Support
Company-described pharmacist support, physician-advisor consultation for complex questions, patient/order tracking, licensed preparation, and lot documentation. Supports offered service descriptions, not a transfer of prescribing responsibility or independent efficacy certification.
- Allergychoices: Allergychoices Pharmacy
Company-described named-patient preparation according to provider prescriptions, FDA-approved source extracts, lot tracking, portal services, counseling, interpreter support, and prescription pricing on request by phone. Numeric prices, service footprint, shipping promises, storage windows, and outcome claims are not reproduced. Pharmacy pricing given by phone is not an all-in patient bill or practice program quote.
